Skip to content
Open access

Multiple mechanisms regulate the nanoscale organization of PD-L1 at the cell surface

Aug 2026 · bioRxiv · 0 citations · 44 references
Biology

TL;DR

It is found that PD-L1 is organized into nanoscale clusters at the plasma membrane, with distinct regulatory roles for the actin cytoskeleton, galectin-3, and cholesterol within the plasma membrane of tumor cells.

Abstract

The immune checkpoint protein PD-L1 plays a pivotal role in tumor immune evasion by binding to PD-1 on immune cells, including T lymphocytes. While the expression and function of PD-L1 have been well studied, the importance of its spatial organization on the cell surface of tumor cells remains poorly understood. In this study, we used super-resolution microscopy combined with biochemical perturbations to investigate the factors regulating PD-L1 clustering and its effects on PD-1 binding and T cell inhibition. We found that PD-L1 is organized into nanoscale clusters at the plasma membrane, with distinct regulatory roles for the actin cytoskeleton, galectin-3, and cholesterol. Disruption of cortical actin increased PD-L1 cluster size, while galectin-3 promoted smaller, denser clusters and increased PD-L1 lateral mobility. Cholesterol depletion reduced PD-L1 cluster size and number and impaired PD-1 binding. These findings indicate that PD-L1 surface organization is collectively regulated by the actin cytoskeleton, galectin-3, and membrane cholesterol within the plasma membrane of tumour cells. Our results provide new insights into the dynamic regulation of PD-L1 and its potential as a therapeutic target in cancer immunotherapy.

Read PDF

Similar papers

Aug 2026

Elucidating the mechanism of ADAM10/PD-L1 interaction in pancreatic adenocarcinoma cell lines using cellular and computational analyses.

This study elucidates the mechanism of ADAM10/PD-L1 interaction in the pancreatic adenocarcinoma cell line, PANC-1, using cellular assays, molecular docking, and molecular dynamics simulations to elucidate how ADAM10 recognizes and interacts with PD-L1, facilitating its cleavage.

Ahmed M. E. Abdalla, Yu Miao, Yasir A. Taha et al. · 0 citations
Review Open access Oct 2026

CAPRIN-1: molecular functions, oncogenic impact and emerging roles in the immune system

Cell cycle-associated protein 1 (CAPRIN-1) is an RNA-binding protein involved in multiple cellular processes, including cell proliferation, differentiation and stress responses. It exerts its functions by regulating the stability and translation of specific messenger RNAs as well as by promoting stress granule format...

A. Aleidan · 0 citations
Open access Sep 2026

A Novel PD-L1 Splice Isoform Modulates β Cell Communication in Response to Interferon Signaling

β cell expression of the immune checkpoint ligand PD-L1 (encoded by CD274) limits autoimmune β cell destruction in type 1 diabetes (T1D). β cell display PD-L1 not only at the cell surface but also secreted on extracellular vesicles (EVs), which bind PD-1 and restrain CD8+ T cell activation. β cell IFN signaling is an e...

Chaitra Rao, Fei Huang, Saptarshi Roy et al. · 0 citations
Open access Sep 2026

LIM and SH3 protein 1 deficiency confers resistance to cytotoxic lymphocyte-mediated lysis and immunotherapy in gastric cancer by disrupting cytoskeleton dynamics

Abstract Background A substantial amount of research has been dedicated to the mechanisms by which tumor cells evade immune system recognition and manipulate the immune microenvironment to facilitate immune escape. Recent studies have shown that viruses and tumors can protect themselves from immune cytotoxicity by remo...

Te-Ming Zhang, Ying-Ying Sun, Chao Chen et al. · 0 citations
Sep 2026

PAG supports T cell immune synapse function by binding to actin.

Immunotherapies affect T cell function by modifying the immune synapse, which forms at the interface between T cells and their targets. Phosphoprotein associated with glycosphingolipid-rich microdomains 1 (PAG) is a T cell adaptor protein within the immune synapse that mediates signaling by the inhibitory co-receptor P...

Emily K. Moore, Shoiab Bukhari, Justin C. Zhong et al. · 0 citations
Open access Sep 2026

Dendritic cell PD-L2 restrains intratumoral CD8+ T cell immunity

Blockade of inhibitory PD-1 signaling on T cells is a cornerstone of cancer immunotherapy, with current strategies targeting PD-1 or its ligand PD-L1. However, PD-1 engages an alternative ligand, PD-L2, whose role in tumor immunity remains poorly defined. Here, we show that PD-L2 is upregulated on intratumoral CCR7⁺ co...

Jinwoo Nah, Amanda Sun, Anushka Yadav et al. · 0 citations

We use cookies to run the site and, with your consent, for analytics and to show ads. See our Cookie Policy.